Evidence map›Paper›PMID 25414253›Full record

ReviewArteriosclerosis, thrombosis, and vascular biology2015

Treating atherosclerosis with regulatory T cells.

Amanda C Foks, Andrew H Lichtman, Johan Kuiper

Open access · greenAbstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Arteriosclerosis, thrombosis, and vascular biology, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 122 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
122citing papers in PubMed, 1 pooled it
5.6field-weighted citation impact, top 3% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

122 citing papers in PubMed, 1 synthesis or guideline pooled it, 199 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Article
  4. Review
  5. Review
  6. Article
  7. Review
  8. Article
  9. Monocytes/Macrophages and Atherogenesis.International journal of molecular sciences · 2025
    Review
  10. Article
  11. Review
  12. Article
  13. Review
  14. Review
  15. Review
  16. Review
  17. Review
  18. Review
  19. Article
  20. Article

62 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors at 1 institution in 1 country.

Amanda C FoksFrom the Department of Pathology, Brigham and Women's Hospital and Harvard Medical School, Boston, MA (A.C.F., A.H.L.); and Division of Biopharmaceutics, Leiden Academic Centre for Drug Research, Leiden University, Gorlaeus Laboratories, Leiden, The Netherlands (J.K.).
Andrew H LichtmanFrom the Department of Pathology, Brigham and Women's Hospital and Harvard Medical School, Boston, MA (A.C.F., A.H.L.); and Division of Biopharmaceutics, Leiden Academic Centre for Drug Research, Leiden University, Gorlaeus Laboratories, Leiden, The Netherlands (J.K.).
Johan KuiperFrom the Department of Pathology, Brigham and Women's Hospital and Harvard Medical School, Boston, MA (A.C.F., A.H.L.); and Division of Biopharmaceutics, Leiden Academic Centre for Drug Research, Leiden University, Gorlaeus Laboratories, Leiden, The Netherlands (J.K.). j.kuiper@lacdr.leidenuniv.nl.
Leiden University · NL

Funding

Regulation of T Cell Responses in AtherosclerosisR01HL087282 · NHLBI · BRIGHAM AND WOMEN'S HOSPITAL · PI LICHTMAN, ANDREW H · 2007 to 2015
$4.0M
NHLBI NIH HHS R01 HL087282NHLBI NIH HHS R01HL087282
6 · The paper itself

Abstract

Regulatory T cells (Tregs) play an important role in the regulation of T-cell-mediated immune responses through suppression of T-cell proliferation and secretion of inhibitory cytokines, such as interleukin-10 and transforming growth factor-β. Impaired Treg numbers and function have been associated with numerous diseases, and an imbalance between proinflammatory/proatherogenic cells and Tregs promotes atherosclerotic disease. Restoration of this balance by inducing Tregs has great therapeutic potential to prevent cardiovascular disease. In addition to suppressing differentiation and function of effector T cells, Tregs have been shown to induce anti-inflammatory macrophages, inhibit foam cell formation and to influence cholesterol metabolism. Furthermore, Tregs suppress immune responses of endothelial cells and innate lymphoid cells. In this review, we focus on the recent knowledge on Treg subsets, their activity and function in atherosclerosis, and discuss promising strategies to use Tregs as a therapeutic tool to prevent cardiovascular disease.

Indexed as

Adoptive TransferAnimalsAtherosclerosisDendritic CellsHumansImmunity, CellularImmunologic FactorsInflammationInflammation MediatorsLymphocyte ActivationMacrophagesPhenotypeSignal TransductionT-Lymphocytes, RegulatoryImmunologic FactorsInflammation Mediatorsatherosclerosisimmune system

Identifiers

PMID25414253
PMCPMC4715365
OpenAlexW2114728915

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.